Search research articles
Contact Us
Filters
Showing results (291-300 of 315) with videos related to
Page
of 32
Sort By:
Neurology
|
January 13, 2010
Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia
P Bourgeat, G Chételat, V L Villemagne, et al.
Molecular Psychiatry
|
October 8, 2014
APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease
Y Y Lim, V L Villemagne, S M Laws, et al.
Journal of Neurochemistry
|
June 1, 1999
Intracellular accumulation of detergent-soluble amyloidogenic A beta fragment of Alzheimer's disease precursor protein in the hippocampus of aged transgenic mice
Q X Li, C Maynard, R Cappai, et al.
Biochemistry
|
July 4, 2001
Copper and zinc binding modulates the aggregation and neurotoxic properties of the prion peptide PrP106-126
M F Jobling, X Huang, L R Stewart, et al.
Neuropsychologia
|
March 18, 2008
Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease
V L Villemagne, K E Pike, D Darby, et al.
European Journal of Biochemistry
|
December 20, 2000
Interaction of linear homologous DNA duplexes via Holliday junction formation
M G Yakubovskaya, A A Neschastnova, K E Humphrey, et al.
Acta Neuropathologica
|
June 19, 2002
Consensus neuropathological diagnosis of common dementia syndromes: testing and standardising the use of multiple diagnostic criteria
G Halliday, T Ng, M Rodriguez, et al.
Translational Psychiatry
|
November 22, 2012
Intense physical activity is associated with cognitive performance in the elderly
B M Brown, J J Peiffer, H R Sohrabi, et al.
Translational Psychiatry
|
February 28, 2013
Retinal vascular biomarkers for early detection and monitoring of Alzheimer's disease
S Frost, Y Kanagasingam, H Sohrabi, et al.
The Journal of Prevention of Alzheimer'S Disease
|
June 25, 2023
Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force
D Angioni, O Hansson, R J Bateman, et al.
Page
of 32
Search research articles
Search
Showing results (291-300 of 315) with videos related to
Sort By:
Page
of 32
Neurology
|
January 13, 2010
Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia
P Bourgeat, G Chételat, V L Villemagne, et al.
Molecular Psychiatry
|
October 8, 2014
APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease
Y Y Lim, V L Villemagne, S M Laws, et al.
Journal of Neurochemistry
|
June 1, 1999
Intracellular accumulation of detergent-soluble amyloidogenic A beta fragment of Alzheimer's disease precursor protein in the hippocampus of aged transgenic mice
Q X Li, C Maynard, R Cappai, et al.
Biochemistry
|
July 4, 2001
Copper and zinc binding modulates the aggregation and neurotoxic properties of the prion peptide PrP106-126
M F Jobling, X Huang, L R Stewart, et al.
Neuropsychologia
|
March 18, 2008
Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease
V L Villemagne, K E Pike, D Darby, et al.
European Journal of Biochemistry
|
December 20, 2000
Interaction of linear homologous DNA duplexes via Holliday junction formation
M G Yakubovskaya, A A Neschastnova, K E Humphrey, et al.
Acta Neuropathologica
|
June 19, 2002
Consensus neuropathological diagnosis of common dementia syndromes: testing and standardising the use of multiple diagnostic criteria
G Halliday, T Ng, M Rodriguez, et al.
Translational Psychiatry
|
November 22, 2012
Intense physical activity is associated with cognitive performance in the elderly
B M Brown, J J Peiffer, H R Sohrabi, et al.
Translational Psychiatry
|
February 28, 2013
Retinal vascular biomarkers for early detection and monitoring of Alzheimer's disease
S Frost, Y Kanagasingam, H Sohrabi, et al.
The Journal of Prevention of Alzheimer'S Disease
|
June 25, 2023
Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force
D Angioni, O Hansson, R J Bateman, et al.
Page
of 32